Merola Joseph F, Tian Haijun, Patil Dhaval, Richardson Craig, Scott Amie, Chen Yen-Hua, Kim Nina, Hur Peter, Armstrong April W
Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
Novartis Pharmaceuticals Corporation, East Hanover, New Jersey.
J Am Acad Dermatol. 2022 Apr;86(4):748-757. doi: 10.1016/j.jaad.2021.09.019. Epub 2021 Sep 20.
Among patients in the United States with psoriasis (PsO), limited data exist on the incidence and prevalence of psoriatic arthritis (PsA) based on disease severity.
To assess the incidence, prevalence, and predictors of PsA among patients with PsO stratified by PsO severity using treatment type.
Incidence of PsA per 100 PsO patient-years (PY) and prevalence were assessed using the Optum electronic health records database. Incidence was assessed from PsO diagnosis and 1 year after PsO diagnosis overall and stratified by mutually exclusive treatment classes as a severity surrogate.
The overall incidence of PsA was 2.9 (95% CI, 2.9-3.0) events per 100 PY. The incidence (95% CI) by severity surrogate was 2.1 (2.1-2.1), 9.9 (9.5-10.4), and 17.6 (16.9-18.3) events per 100 PY for patients with mild, moderate, and severe PsO as determined by receiving nonsystemics, nonbiologic systemic therapy, and biologics, respectively. When excluding patients diagnosed with PsA 1 year after PsO diagnosis, overall incidence was lower (1.7 [95% CI, 1.6-1.7] events per 100 PY), with similar trends for treatment-severity surrogates.
Results may not be generalizable to a wider population.
The risk of developing PsA increased with disease severity and was highest in patients with the most severe PsO.
在美国,关于银屑病(PsO)患者中基于疾病严重程度的银屑病关节炎(PsA)发病率和患病率的数据有限。
使用治疗类型,评估按PsO严重程度分层的PsO患者中PsA的发病率、患病率及预测因素。
使用Optum电子健康记录数据库评估每100 PsO患者年(PY)的PsA发病率和患病率。从PsO诊断时及PsO诊断后1年总体评估发病率,并按相互排斥的治疗类别分层作为严重程度替代指标。
PsA的总体发病率为每100 PY 2.9(95%CI,2.9 - 3.0)例。根据严重程度替代指标,轻度、中度和重度PsO患者(分别通过接受非系统性药物、非生物系统性治疗和生物制剂确定)的发病率(95%CI)分别为每100 PY 2.1(2.1 - 2.1)例、9.9(9.5 - 10.4)例和17.6(16.9 - 18.3)例。排除PsO诊断后1年诊断为PsA的患者后,总体发病率较低(每100 PY 1.7 [95%CI,1.6 - 1.7]例),治疗 - 严重程度替代指标的趋势相似。
结果可能无法推广到更广泛的人群。
发生PsA的风险随疾病严重程度增加,在最严重的PsO患者中最高。